Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
About this item
Full title
Author / Creator
Palumbo, Antonio , Chanan-Khan, Asher , Weisel, Katja , Nooka, Ajay K , Masszi, Tamas , Beksac, Meral , Spicka, Ivan , Hungria, Vania , Munder, Markus , Mateos, Maria V , Mark, Tomer M , Qi, Ming , Schecter, Jordan , Amin, Himal , Qin, Xiang , Deraedt, William , Ahmadi, Tahamtan , Spencer, Andrew , Sonneveld, Pieter and CASTOR Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a study involving patients with refractory multiple myeloma, the anti-CD38 antibody daratumumab in combination with bortezomib and dexamethasone resulted in longer progression-free survival and a higher rate of response than bortezomib and dexamethasone alone.
Multiple myeloma is associated with organ dysfunction, including bone lesions, anem...
Alternative Titles
Full title
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Authors, Artists and Contributors
Author / Creator
Chanan-Khan, Asher
Weisel, Katja
Nooka, Ajay K
Masszi, Tamas
Beksac, Meral
Spicka, Ivan
Hungria, Vania
Munder, Markus
Mateos, Maria V
Mark, Tomer M
Qi, Ming
Schecter, Jordan
Amin, Himal
Qin, Xiang
Deraedt, William
Ahmadi, Tahamtan
Spencer, Andrew
Sonneveld, Pieter
CASTOR Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1814655716
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1814655716
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1606038
